Enterprise Value
-17.73M
Cash
201M
Avg Qtr Burn
-23.92M
Short % of Float
13.56%
Insider Ownership
0.39%
Institutional Own.
93.66%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
exarafenib (KN-2787) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
Phase 1 Data readout |